Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
12
2020
revised:
03
06
2021
accepted:
26
06
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
29
1
2022
Statut:
epublish
Résumé
Regular physical activity (PA) can affect oxidative stress, known to be involved in carcinogenesis. The objective of this study was to evaluate the associations between a six-month PA intervention and oxidative stress biomarkers, PA, and clinical outcomes in patients with metastatic breast cancer. Forty-nine newly diagnosed patients with metastatic breast cancer were recruited for a single-arm, unsupervised, and personalized six-month walking intervention with activity tracker. PA level and PA fitness, plasma concentrations of DNA oxidation (8OhdG), lipid peroxidation (MDA), and protein oxidation (AOPP), plasma activities of superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase, plasma and leucocyte activities of myeloperoxidase (MPO) and NADPH oxidase (NOX), and clinical markers of tumor progression (RECIST criteria) were measured at baseline and after the six-month intervention. GPX activity (+17%) and MDA (+9%) significantly increased between baseline and the end of the intervention. Changes in PA level and fitness were significantly positively correlated with changes in plasma GPX and significantly negatively with changes in NOX in the leucocytes. Plasma MDA was significantly higher (+20%) whereas plasma AOPP was lower (-46%) for patients with tumor progression or that died during the six months as compared to patients without progression. A six-month PA intervention may be potentially beneficial in metastatic breast cancer patients for enhancing antioxidant enzyme activity and decreasing prooxidant enzyme activity. Moreover, AOPP and MDA could also be favorable and unfavorable biomarkers, respectively, since they are associated with disease progression and fitness level in this population. This trial is registered with NCT number: NCT03148886.
Identifiants
pubmed: 34326920
doi: 10.1155/2021/6694594
pmc: PMC8302399
doi:
Banques de données
ClinicalTrials.gov
['NCT03148886']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6694594Informations de copyright
Copyright © 2021 Lidia Delrieu et al.
Déclaration de conflit d'intérêts
No author reports any competing financial interest.
Références
Cardiovasc Res. 2005 Aug 1;67(2):187-97
pubmed: 15935334
Free Radic Res. 2014 Jan;48(1):93-108
pubmed: 24060092
Menopause. 2013 Oct;20(10):1036-42
pubmed: 23481124
Free Radic Biol Med. 2012 Mar 15;52(6):993-1002
pubmed: 22245095
Eur J Nutr. 2008 May;47 Suppl 2:19-28
pubmed: 18458832
Clin Chem. 1995 Dec;41(12 Pt 2):1819-28
pubmed: 7497639
Oncologist. 2005;10 Suppl 3:20-9
pubmed: 16368868
BMC Cancer. 2020 Jul 3;20(1):622
pubmed: 32620149
J Investig Med. 2009 Aug;57(6):720-3
pubmed: 19494787
Ann Biol Clin (Paris). 1998 May-Jun;56(3):305-19
pubmed: 9754263
Antioxid Redox Signal. 2018 Jun 10;28(17):1576-1581
pubmed: 28990416
Acta Physiol (Oxf). 2019 Feb;225(2):e13159
pubmed: 29947475
Hypertension. 2009 Nov;54(5):1014-20
pubmed: 19786647
J Rehabil Med. 2013 Jun;45(6):572-9
pubmed: 23708239
Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):639-44
pubmed: 16614103
Pediatr Exerc Sci. 2015 Feb;27(1):67-76
pubmed: 25387489
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597313
Adv Clin Chem. 2008;46:1-50
pubmed: 19004186
Front Physiol. 2016 Nov 07;7:486
pubmed: 27872595
Singapore Med J. 2008 Aug;49(8):640-3
pubmed: 18756349
Asian Pac J Cancer Prev. 2013;14(5):2845-50
pubmed: 23803042
J Natl Cancer Inst. 2012 Jun 6;104(11):815-40
pubmed: 22570317
JMIR Res Protoc. 2018 Aug 30;7(8):e10487
pubmed: 30166274
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2557-63
pubmed: 8637913
Antioxid Redox Signal. 2000 Winter;2(4):903-17
pubmed: 11213491
J Clin Pathol. 1989 Oct;42(10):1046-8
pubmed: 2584405
Cancer Biomark. 2010;6(2):95-103
pubmed: 20571235
Genes Dev. 2000 Apr 15;14(8):927-39
pubmed: 10783165
Kidney Int. 1996 May;49(5):1304-13
pubmed: 8731095
Nat Rev Cancer. 2003 Apr;3(4):276-85
pubmed: 12671666
Ann Surg Oncol. 2014 Dec;21(13):4139-43
pubmed: 24962940
Redox Rep. 2011;16(6):223-9
pubmed: 22195989
JMIR Mhealth Uhealth. 2020 Jan 28;8(1):e12306
pubmed: 32012082
Int J Cancer. 2012 Jan 15;130(2):338-48
pubmed: 21351093
J Cancer Surviv. 2010 Jun;4(2):87-100
pubmed: 20052559
Free Radic Res. 2012 Jan;46(1):2-10
pubmed: 22035543
J Phys Act Health. 2011 Aug;8(6):858-65
pubmed: 21832302
Clin Chim Acta. 2006 Mar;365(1-2):30-49
pubmed: 16214123
Free Radic Biol Med. 2008 Feb 15;44(4):558-69
pubmed: 18005669
Antioxid Redox Signal. 2011 Aug 15;15(4):903-9
pubmed: 21446882
J Cancer Res Clin Oncol. 2012 Jun;138(6):999-1009
pubmed: 22362301
Ann Oncol. 1997 Apr;8(4):335-41
pubmed: 9209662